References
- Abdel-Mannan O, Venkatesan TC, Sutcliffe AG. Paediatric sudden unexpected death in epilepsy (SUDEP): is it truly unexplained? Paediatr Child Health. 2022 Oct; 32 (10): 328-87. DOI: 10.1016/j. paed.2022.07.010
- Xu C, Gong Y, Wang Y, Chen Z. New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments. Pharmacol Ther. 2022 May; 233: 108026. DOI: 10.1016/j.pharmthera.2021.108026
- Guery D, Rheims S. Clinical management of drug resistant epilepsy: a review on current strategies. Neuropsychiatr Dis Treat. 2021 Jul; 17: 2229-42. DOI: 10.2147/NDT.S256699
- Kobylarek D, Iwanowski P, Lewandowska Z, Limphaibool N, Szafranek S, Labrzycka A, et al. Advances in the potential biomarkers of epilepsy. Front Neurol. 2019 Jul; 10: 685. DOI: 10.3389/fneur.2019.00685
- Yuan J, Ran X, Liu K, Yao C, Yao Y, Wu H, et al.. Machine learning applications on neuroimaging for diagnosis and prognosis of epilepsy: a review. J Neurosci Methods. 2022 Feb;368(4):109441. DOI: 10.1016/j.jneumeth.2021.109441
- Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010 Jun; 51(6): 1069-77. DOI: 10.1111/j.1528-1167.2009.02397.x
- Gallotto S, Seeck M. EEG biomarker candidates for the identification of epilepsy. Clin Neurophysiol Prac. 2023 Dec; 8: 32-41. DOI: 10.1016/j.cnp.2022.11.004
- Zamay TN, Zamay GS, Shnayder NA, Dmitrenko DV, Zamay SS, Yushchenko V, et al. Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages. Mol Ther Nucleic Acids. 2020 Mar; 19: 157-67. DOI: 10.1016/j.omtn.2019.10.042
- Niraula A, Thapa S, Kunwar S, Lamsal M, Baral N, Maskey R. Adenosine deaminase activity in type 2 diabetes mellitus: does it have any role? BMC Endocr Disord. 2018 Aug; 18: 1-5. DOI: 10.1186/s12902-018-0284-9
- Ling Y, Jiang C, Xiao Z, Shang X, Li Q, Wang B, et al. Serum adenosine deaminase activity and acute cerebral infarction: a retrospective case-control study based on 7913 participants. Aging (Albany NY). 2022 Oct; 14(21): 8719-28. DOI: 10.18632/aging.204338
- Giusti G. Adenosine deaminase. In:Bergmeyer HU (ed), Methods of Enzymatic Analysis (2nd ed). Academic Press, New York 1974, pp 1092-1099. DOI: 10.1016/B978-0-12-091302-2.50108-0
- Surguchov A, Surgucheva I, Sharma M, Sharma R, Singh V. Pore-forming proteins as mediators of novel epigenetic mechanism of epilepsy. Front Neurol. 2017 Jan; 8: 1-8. DOI: 10.3389/fneur.2017.00003
- Choi J, Kim SY, Kim H, Lim BC, Hwang H, Chae JH, et al. Serum α-synuclein and IL-1β are increased and correlated with measures of disease severity in children with epilepsy: potential prognostic biomarkers? BMC Neurol. 2020 March; 20(85): 1-11. DOI: 10.1186/s12883-020-01662-y
- Şimşek F, Ceylan M, Aşkın S, Kızıltunç A. Serum Myeloperoxidase, Malondialdehyde, Alpha-Synuclein Levels in Patients with Epilepsy. MNJ (Malang Neurology Journal). 2021 July;7(2):93-7. DOI: 10.21776/ub.mnj.2021.007.02.2
- Rong H, Jin L, Wei W, Wang X, Xi Z. Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy. Seizure. 2015 Apr; 27: 6-9. DOI: 10.1016/j. seizure.2015.02.007
- Bazhanova ED, Kozlov AA, Litovchenko AV. Mechanisms of drug resistance in the pathogenesis of epilepsy: role of neuroinflammation. A literature review. Brain Sci. 2021 May; 11(5): 663. DOI: 10.3390/brainsci11050663
- Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015 Dec; 1628: 298-316. DOI: 10.1016/j. brainres.2015.07.005
- Mesraoua B, Deleu D, Kullmann DM, Shetty AK, Boon P, Perucca E, et al. Novel therapies for epilepsy in the pipeline. Epilepsy Behav. 2019 Aug; 97: 282-90. DOI: 10.1016/j.yebeh.2019.04.042
- Asadi-Pooya A, Sperling MR. Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy. Med Hypotheses. 2007 Mar; 69(3): 560-3. DOI: 10.1016/j. mehy.2006.12.054
- Potschka H, Fedrowitz M, Löscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett. 2002 Jul: 327(3); 173-6. DOI: 10.1016/S0304-3940(02)00423-8
- Baltes S, Gastens A, Fedrowitz M, Potschka H, Kaever V, Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb; 52(2): 333-46. DOI: 10.1016/j.neuropharm.2006.07.038
- Gomes CV, Kaster MP, Tomé AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta. 2011 May;1808(5):1380-99. DOI: 10.1016/j.bbamem.2010.12.001
- Dupere JR, Dale TJ, Starkey SJ, Xie X. The anticonvulsant BW534U87 depresses epileptiform activity in rat hippocampal slices by an adenosine-dependent mechanism and through inhibition of voltage-gated Na+ channels. Br J Pharmacol. 1999 Nov; 128(5): 1011-20. DOI: 10.1038/sj.bjp.0702881
- Southam E, Stratton SC, Sargent RS, Brackenborough KT, Duffy C, Hagan RM, et al. Broad spectrum anticonvulsant activity of BW534U87: possible role of an adenosine-dependent mechanism. Pharmacol Biochem Behav. 2002 Dec;74(1): 111-8. DOI: 10.1016/S0091-3057(02)00956-5
- de Groot M, Iyer A, Zurolo E, Anink J, Heimans JJ, Boison D, et al. Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia. 2012 Jan; 53(1): 58-66. DOI: 10.1111/j.1528-1167.2011.03306.x
- Huang J, He Y, Chen M, Du J, Li G, Li S, et al. Adenosine deaminase and adenosine kinase expression in human glioma and their correlation with glioma associated epilepsy. Mol Med Rep. 2015 Nov;12(5):6509-16. DOI: 10.3892/mmr.2015.4285